Connection

Campbell McInnes to Antineoplastic Agents

This is a "connection" page, showing publications Campbell McInnes has written about Antineoplastic Agents.
Connection Strength

2.418
  1. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.
    View in: PubMed
    Score: 0.453
  2. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
    View in: PubMed
    Score: 0.444
  3. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem. 2015 Jan 08; 58(1):433-42.
    View in: PubMed
    Score: 0.276
  4. PLK1 as an oncology target: current status and future potential. Drug Discov Today. 2011 Jul; 16(13-14):619-25.
    View in: PubMed
    Score: 0.215
  5. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem Pharmacol. 2009 May 15; 77(10):1561-71.
    View in: PubMed
    Score: 0.183
  6. Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discov Today. 2008 Oct; 13(19-20):875-81.
    View in: PubMed
    Score: 0.178
  7. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs. 2006 Apr; 9(4):273-8.
    View in: PubMed
    Score: 0.151
  8. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem. 2005; 5(2):181-97.
    View in: PubMed
    Score: 0.139
  9. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents. 2003 Jan; 3(1):57-69.
    View in: PubMed
    Score: 0.121
  10. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
    View in: PubMed
    Score: 0.109
  11. Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014 Jul; 9(7):773-89.
    View in: PubMed
    Score: 0.066
  12. Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol. 2010 Oct 29; 17(10):1111-21.
    View in: PubMed
    Score: 0.052
  13. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. J Med Chem. 2010 Mar 11; 53(5):2136-45.
    View in: PubMed
    Score: 0.012
  14. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
    View in: PubMed
    Score: 0.011
  15. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem. 2004 Mar 25; 47(7):1662-75.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.